Business Standard

Second Pfizer shot after 12 weeks produces more antibodies: Study

Extending 2nd dose interval increases the peak antibody response 3.5-fold

Pfizer to acquire oncology specialist Medivation for $ 14 bn
Premium

After Britain moved to extend the interval between doses, Pfizer and vaccine partner BioNTech said there was no data to back up the move

Alistair Smout | Reuters London
Pfizer's Covid-19 vaccine generates antibody responses three-and-a-half times larger in older people when a second dose is delayed to 12 weeks after the first, a British study said.
 
The study released on Friday is the first to directly compare immune responses of the Pfizer shot from the three-week dosing interval tested in clinical trials, and the extended 12-week interval that British officials recommend in order to give more vulnerable people at least some protection quickly.
 
After Britain moved to extend the interval between doses, Pfizer and vaccine partner BioNTech said there was no data to back up the

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in